Literature DB >> 10499853

Diagnosis of bovine brucellosis by skin test: conditions for the test and evaluation of its performance.

C Saegerman1, T K Vo, L De Waele, D Gilson, A Bastin, G Dubray, P Flanagan, J N Limet, J J Letesson, J Godfroid.   

Abstract

Brucellergene OCB (Rhône-Mérieux) was used as an allergen to define the intrinsic parameters of a skin test and to compare its properties with serology for the diagnosis of bovine brucellosis. The skin test was also evaluated for its capacity to solve problems associated with false positive reactions in serological tests. The optimal reading delay for the skin test was 72 hours. The brucellosis allergic reaction was two to three times less intense than the tuberculosis allergic reaction. An increase of 1.1 mm or more in the skin thickness was therefore considered to be an adequate cut-off. The specificity calculated for 1192 brucellosis-free animals (including animals from brucellosis-free herds in which false positive serological reactions had been reported) was 99-83 per cent (95 per cent confidence interval [CI] 99-40 to 99-98 per cent). The sensitivity determined from 27 experimentally infected heifers ranged from 93 per cent (95 per cent CI 76 to 100 per cent) to 78 per cent (95 per cent CI 58 to 91 per cent) when measured respectively one and six months after the infection. Allergic reactions could be detected in vaccinated animals up to four-and-a-half years after the vaccination. On the other hand, no sensitisation was recorded in naïve animals after up to eight monthly injections of the allergen. The skin test gave valuable information, in combination with the serological tests, in both acute and chronic brucellosis. The skin test discriminated brucellosis clearly from false positive serological reactions due to infections with Yersinia enterocolitica O9.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10499853     DOI: 10.1136/vr.145.8.214

Source DB:  PubMed          Journal:  Vet Rec        ISSN: 0042-4900            Impact factor:   2.695


  7 in total

1.  Documenting the absence of brucellosis in cattle, goats and dogs in a "One Health" interface in the Mnisi community, Limpopo, South Africa.

Authors:  Gregory Simpson; Tanguy Marcotty; Elodie Rouille; Nelson Matekwe; Jean-Jacques Letesson; Jacques Godfroid
Journal:  Trop Anim Health Prod       Date:  2017-12-23       Impact factor: 1.559

2.  Yersinia enterocolitica as a vehicle for a naked DNA vaccine encoding Brucella abortus bacterioferritin or P39 antigen.

Authors:  Ayman Al-Mariri; Anne Tibor; Pascal Lestrate; Pascal Mertens; Xavier De Bolle; Jean-Jacques Letesson
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

Review 3.  Diagnosis of brucellosis in livestock and wildlife.

Authors:  Jacques Godfroid; Klaus Nielsen; Claude Saegerman
Journal:  Croat Med J       Date:  2010-08       Impact factor: 1.351

4.  Efficacy of several serological tests and antigens for diagnosis of bovine brucellosis in the presence of false-positive serological results due to Yersinia enterocolitica O:9.

Authors:  P M Muñoz; C M Marín; D Monreal; D González; B Garin-Bastuji; R Díaz; R C Mainar-Jaime; I Moriyón; J M Blasco
Journal:  Clin Diagn Lab Immunol       Date:  2005-01

5.  Environment and Offspring Surveillance in Porcine Brucellosis.

Authors:  Agustín Rebollada-Merino; Marta Pérez-Sancho; Antonio Rodríguez-Bertos; Nerea García; Irene Martínez; Alejandro Navarro; Lucas Domínguez; Teresa García-Seco
Journal:  Front Vet Sci       Date:  2022-06-21

6.  An evaluation of Irish cattle herds with inconclusive serological evidence of bovine brucellosis.

Authors:  M Hayes; S Ashe; Dm Collins; S Power; K Kenny; M Sheahan; G O'Hagan; Sj More
Journal:  Ir Vet J       Date:  2009-03-01       Impact factor: 2.146

7.  Immunological response to Brucella abortus strain 19 vaccination of cattle in a communal area in South Africa.

Authors:  Gregory J G Simpson; Tanguy Marcotty; Elodie Rouille; Abel Chilundo; Jean-Jacques Letteson; Jacques Godfroid
Journal:  J S Afr Vet Assoc       Date:  2018-03-29       Impact factor: 1.474

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.